Evaluation of PE_PGRS33 as a potential surface target for humoral responses against Mycobacterium tuberculosis

Mariachiara Minerva1, Flavio De Maio1, Serena Camassa1

  • 1Institute of Microbiology, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario Gemelli, 00168 Rome, Italy.

Pathogens and Disease
|September 16, 2017
PubMed

Insights

Targeting Mycobacterium tuberculosis PE_PGRS33 with antibodies can block bacterial entry into macrophages and reduce inflammation. This study shows PE_PGRS33 is a promising target for tuberculosis humoral response therapies.

Area of Science:

  • Immunology
  • Microbiology
  • Molecular Biology

Background:

  • Mycobacterium tuberculosis (Mtb) PE_PGRS33 is a surface protein.
  • It interacts with Toll-like receptor 2 on macrophages, inducing inflammation and promoting Mtb entry.

Purpose of the Study:

  • Investigate PE_PGRS33 as a target for humoral immune response.
  • Aim to hinder key tuberculosis pathogenesis processes.

Main Methods:

  • Expressed and purified native PE_PGRS33 protein in E. coli.
  • Raised polyclonal antiserum against native PE_PGRS33.
  • Tested antiserum's effect on Mtb entry, inflammation, and in vivo M. smegmatis restriction.

Main Results:

  • Purified PE_PGRS33 elicited proinflammatory signals in macrophages.
  • Anti-PE_PGRS33 serum inhibited Mtb entry and neutralized PE_PGRS33's proinflammatory activity.
  • Mice immunized with native PE_PGRS33 restricted M. smegmatis in vivo.

Conclusions:

  • PE_PGRS33 is a potential target for a neutralizing humoral response against tuberculosis.
  • Antibodies against PE_PGRS33 can block Mtb pathogenesis.
  • Native recombinant PE_PGRS33 vaccination shows in vivo efficacy.